Recipharm enters into partnership with AstraZeneca for Swedish biomanufacturing facility
It is announced today that Recipharm will move into biomanufacturing with the acquisition of a majority stake in AstraZeneca’s biotech laboratory located in Södertälje, Sweden.
A newly formed subsidiary will be created called Recipharm Biotech AB and around 30 employees will transfer to the new company. The facility is able to develop and produce recombinant proteins and monoclonal antibodies for use in clinical trials. It is anticipated that the facility will be handed over on 1 January 2009.